Mustafa Zelal Muallem1, Khayal Gasimli2, Rolf Richter3, Jumana Almuheimid3, Sara Nasser3, Elena Ioana Braicu2, Jalid Sehouli3. 1. Department of Gynecology, Virchow Campus Clinic, Charité Medical University, Berlin, Germany Mustafa-Zelal.Muallem@charite.de. 2. Department of Gynecology, Virchow Campus Clinic, Charité Medical University, Berlin, Germany Ovarian Cancer Tumor Bank, Virchow Campus Clinic, Charité Medical University, Berlin, Germany. 3. Department of Gynecology, Virchow Campus Clinic, Charité Medical University, Berlin, Germany.
Abstract
AIM: The present study aimed to compare the outcome of secondary cytoreductive surgery retrospectively in patients with positive and negative Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) score that were operated on at the Department of Gynecology, Charité Comprehensive Cancer Center, Medical University, between 2006 and 2013. PATIENTS AND METHODS: A total of 209 consecutive patients presenting a first recurrence of epithelial ovarian cancer were enrolled: 139 patients had a positive AGO score, and 70 patients had at least one negative criterion of the AGO score. All patients underwent secondary cytoreductive surgery and data were evaluated retrospectively. RESULTS:Total macroscopic tumor resection was obtained during secondary cytoreductive surgery in 127 patients (61%), 93 (67%) in the AGO-positive group and 34 (48.5%) in the AGO-negative group. Overall (OS) and progression-free survival (PFS) were identical in both groups of patients when secondary cytoreductive surgery succeeded in achieving complete tumor resection. PFS was 22 months in AGO-positive patients who were tumor-free after secondary cytoreductive surgery and 21 months in AGO-negative patients with complete resection after secondary cytoreductive surgery. There were no significant differences in morbidity and mortality rates for both groups. CONCLUSION:AGO score is a useful predictor for operability in patients with a first recurrence of ovarian cancer. Patients with negative scores may still have a 50% chance of achieving optimal tumor resection after secondary cytoreductive surgery. This will be a pivotal factor when counseling patients with recurrent disease regarding further management options. Copyright
RCT Entities:
AIM: The present study aimed to compare the outcome of secondary cytoreductive surgery retrospectively in patients with positive and negative Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) score that were operated on at the Department of Gynecology, Charité Comprehensive Cancer Center, Medical University, between 2006 and 2013. PATIENTS AND METHODS: A total of 209 consecutive patients presenting a first recurrence of epithelial ovarian cancer were enrolled: 139 patients had a positive AGO score, and 70 patients had at least one negative criterion of the AGO score. All patients underwent secondary cytoreductive surgery and data were evaluated retrospectively. RESULTS: Total macroscopic tumor resection was obtained during secondary cytoreductive surgery in 127 patients (61%), 93 (67%) in the AGO-positive group and 34 (48.5%) in the AGO-negative group. Overall (OS) and progression-free survival (PFS) were identical in both groups of patients when secondary cytoreductive surgery succeeded in achieving complete tumor resection. PFS was 22 months in AGO-positive patients who were tumor-free after secondary cytoreductive surgery and 21 months in AGO-negative patients with complete resection after secondary cytoreductive surgery. There were no significant differences in morbidity and mortality rates for both groups. CONCLUSION: AGO score is a useful predictor for operability in patients with a first recurrence of ovarian cancer. Patients with negative scores may still have a 50% chance of achieving optimal tumor resection after secondary cytoreductive surgery. This will be a pivotal factor when counseling patients with recurrent disease regarding further management options. Copyright